Search for content, post, videos

Qlucore presents promising results

Qlucore has presented the first results from an EU-funded project for improved diagnosis of lung cancer.

The presented results, a new classification model, not only separates different subgroups of primary lung cancer but also indicates whether the tumor sample is a metastasis of breast, colorectal, or kidney cell cancer. This information can have significant implications for treatment decisions in future clinical applications, states the company.

A collaboration with Heidelberg University Hospital

In late 2021, Qlucore, together with Heidelberg University Hospital, received a financial grant from the Eurostars Joint European Programme. The new model is a result of this collaboration.

Qlucore Insights & Diagnostics

The new classification model is based on Qlucore’s knowledge and workflows for developing gene expression-based machine learning models (AI-based) and has been trained on hundreds of carefully selected tissue samples from lung cancer.

Qlucore Insights is intended for research and enables early testing and evaluation. Qlucore Insights is provided to hospitals, clinics, and laboratories via Qlucore’s European sales force. Qlucore Diagnostics fills an important gap in the workflow for clinical precision diagnostics, states the company. With disease-specific machine learning models that enable classification and a feature supporting clinical decision-making, including user-friendly 3D visualizations, it becomes possible to predict patients’ responses to treatment. “Qlucore Diagnostics is the future solution for personalized cancer treatment, and the goal is to obtain CE marking,” states the company.

Photo: Qlucore